盐酸文拉法辛胶囊(泽忆)治疗262例抑郁症Ⅳ临床研究  

The IV clinical research of Venlafaxine capsules in the treatment of depression

作　　者：邓小鹏[1] 周丽芳[1] 涂哲明[1] 刘胜皇[1] 蔡德明[1] 刘波[1] 

机构地区：[1]湖北省荆州市精神卫生中心,湖北荆州434000

出　　处：《中国民康医学》2012年第17期2072-2073,共2页Medical Journal of Chinese People’s Health

摘　　要：目的:观察盐酸文拉法辛胶囊治疗抑郁症的疗效及不良反应。方法:通过对全国7家精神病医院的262例抑郁症患者进行多中心,大样本,开放性的为期8周和26周的文拉法辛治疗观察。用汉密尔顿抑郁量表评定病情严重程度,通过减分率计算疗效和记录不良反应出现情况评价安全性。结果:本组在第8周末和第26周末基本痊愈率分别为:54.96%和65.65%,显效率分别为:33.59%和33.21%。不良反应轻微,无一例因药物反应导致治疗中断。结论:文拉法辛治疗抑郁症疗效确切,不良反应轻微,可作为一线抗抑郁药使用。Objective：To research the efficacy and safety of Venlafaxine in the treatment of depression. Methods：262 cases were treated for 26 weeks. HAMD was used to measure the efficacy. Reduction rate was used to measure the Curative effect . Results ： It was found that the basic recovery rate In 8 and 26 weeks is 54.96% and 65.65% , the effective rate In 8 and 26 weeks is 33.59% and 33.21% , Adverse reaction is slight. Conclusions： Venlafaxine show a satisfactory effect and safety in the treatment of depression.

关 键 词：文拉法辛 抑郁症 疗效 不良反应 

分 类 号：R971.43[医药卫生—药品] R749.41[医药卫生—药学]